[Skip to Navigation]
May 15, 2018

Monoclonal Antibodies for Migraine Prevention: Progress, but Not a Panacea

Author Affiliations
  • 1Division of Headache, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
  • 2Jack D. Weiler Hospital, Montefiore Medical Center, Inpatient Services, Montefiore Headache Center, Albert Einstein College of Medicine, Bronx, New York
JAMA. 2018;319(19):1985-1987. doi:10.1001/jama.2018.4852

Migraine is a common chronic condition characterized by recurrent attacks of severe headache with associated symptoms such as light and sound sensitivity, nausea, vomiting, and focal neurological disturbances. In 2016, migraine affected an estimated 1.04 billion people worldwide.1 Migraine prevalence and disease activity are highest among women during their childbearing years.2 Approximately 14% of people with migraine experience 5 or more attacks per month.3 For many patients, migraine episodes are debilitating, and overall, 25% of people with migraine report that they have missed a day of work or school because of migraine in the previous 3 months.3